Spectrophotometric determination of the sulfhydryl containing drug mesna

AbstractFour simple and sensitive spectrophotometric methods were developed for the determination of the sulfhydryl containing drug mesna (MSN). Methods I and II rely on nucleophilic aromatic substitution reactions using two UV tagging reagents namely: 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) for method I and 2,4-dinitrofluorobenzene (DNFB) for method II. Both reactions took place in alkaline buffered medium and the obtained yellowish products were measured at 414 and 332nm for methods I and II, respectively. Methods III and IV are indirect spectrophotometric methods based on the suppressive effect of MSN on the absorption of two ternary complex systems which are composed of 1,10-phenanthroline, silver and eosin for method III and 1,10-phenanthroline, silver and bromopyrogallol red for method IV. The decrease in absorbance of the ternary complexes was measured at 547 and 635nm for methods III and IV, respectively. All the experimental parameters affecting these reactions were carefully studied and optimized. The methods were validated as per the ICH guidelines. The methods were applicable in the linearity ranges 4–18μg/mL for method I, 4–16μg/mL for method II, 0.25–2.25μg/mL for method III and 0.25–1.75μg/mL for method IV. The proposed methods were successfully applied for the analysis of MSN in its commercial ampoules and no interference was encountered from the present excipients as indicated by the satisfactory percentage recoveries. The results obtained were in a good agreement with those obtained from a previously published method of the investigated drug

A validated stability indicating DAD–HPLC method for determination of pentoxifylline in presence of its pharmacopeial related substances

A validated, simple and sensitive stability-indicating HPLC method was introduced for the analysis of Pentoxifylline in the presence of its pharmacopeial related substances, Caffeine anhydrous and Theophylline anhydrous, in the presence of its forced degradation products. This was achieved using a gradient DAD–HPLC method in order to achieve a good separation between the related substance peaks, complying with the pharmacopeial requirement, and an adequate retention time for the Pentoxifylline peak. The method was validated according to the ICH guidelines and different HPLC parameters were optimized for the determination of Pentoxifylline in its dosage form (sustained release tablets). Furthermore, the study of forced degradation of Pentoxifylline was done under various conditions including; hydrolysis (acid, alkaline and neutral), oxidation, dry heat and photo-decomposition. The proposed method could separate Pentoxifylline peak from those of the different forced degradation product peaks and the purity of the Pentoxifylline peak was confirmed using the photo-diode array detector

Clinical and genetic characteristics of late-onset Huntington's disease

Background: The frequency of late-onset Huntington's disease (>59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive. Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Methods: Participants with late- and common-onset (30–50 years)were compared for first clinical symptoms, disease progression, CAG repeat size and family history. Participants with a missing CAG repeat size, a repeat size of ≤35 or a UHDRS motor score of ≤5 were excluded. Results: Of 6007 eligible participants, 687 had late-onset (11.4%) and 3216 (53.5%) common-onset HD. Late-onset (n = 577) had significantly more gait and balance problems as first symptom compared to common-onset (n = 2408) (P <.001). Overall motor and cognitive performance (P <.001) were worse, however only disease motor progression was slower (coefficient, −0.58; SE 0.16; P <.001) compared to the common-onset group. Repeat size was significantly lower in the late-onset (n = 40.8; SD 1.6) compared to common-onset (n = 44.4; SD 2.8) (P <.001). Fewer late-onset patients (n = 451) had a positive family history compared to common-onset (n = 2940) (P <.001). Conclusions: Late-onset patients present more frequently with gait and balance problems as first symptom, and disease progression is not milder compared to common-onset HD patients apart from motor progression. The family history is likely to be negative, which might make diagnosing HD more difficult in this population. However, the balance and gait problems might be helpful in diagnosing HD in elderly patients